Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25521658
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Consult+Pharm
2014 ; 29
(12
): 823-37
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Mirabegron: a Beta-3 agonist for overactive bladder
#MMPMID25521658
Bragg R
; Hebel D
; Vouri SM
; Pitlick JM
Consult Pharm
2014[Dec]; 29
(12
): 823-37
PMID25521658
show ga
OBJECTIVE: To review the literature regarding the efficacy and safety of
mirabegron for the treatment of overactive bladder (OAB). DATA SOURCES: A
literature search was performed using MEDLINE (PubMed) prior to December 31,
2013, using the terms "mirabegron" and "randomized-controlled trial." STUDY
SELECTION/DATA EXTRACTION: All published, double-blind, randomized-controlled
trials assessing mirabegron were included. Articles were reviewed and included if
mirabegron was used as monotherapy and if the primary outcome analyzed drug
efficacy. DATA SYNTHESIS: The efficacy of mirabegron for the treatment of OAB has
been demonstrated in the selected five randomized, placebo-controlled trials. The
majority of these trials lasted 12 weeks and compared various doses of mirabegron
with placebo and/or tolterodine extended-release (ER). Primary efficacy outcomes
for the trials included mean number of micturitions per 24 hours and mean number
of incontinence episodes per 24 hours. Included trials showed statistically
significant reductions in both efficacy outcomes for various doses of mirabegron
when compared with placebo. CONCLUSION: Based on the trials reviewed, mirabegron
has been efficacious in reducing mean number of micturitions and incontinence
episodes per 24 hours, as well as in improving other secondary outcomes such as
OAB symptoms and quality-of-life measures. Common adverse drug events seen with
mirabegron include: hypertension, nasopharyngitis, urinary tract infections,
headache, constipation, upper respiratory tract infection, arthralgia, diarrhea,
tachycardia, abdominal pain, and fatigue. Given the efficacy and safety data
currently available, mirabegron represents a reasonable alternative to
antimuscarinics for patients with OAB. Future studies are needed to determine the
utility of mirabegron for OAB in a variety of demographics.